Erudio Healtherudio.com
Drug
Tucatinib trials: what clinicians said in public
No HCP commentary report on a trial studying tucatinib yet. Erudio has found public clinician commentary on 11 clinical trials studying tucatinib, including HER2CLIMB, HER2CLIMB-05, MOUNTAINEER and TAPUR. Each trial's page lists the podcasts, videos and posts found so far and the price of a report.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| HER2CLIMB-05 NCT05132582 · Seagen, a wholly owned subsidiary of Pfizer DeepView → | HER2+ metastatic breast cancer (first-line maintenance) | Phase 3 | Deep | View | |||
| HER2CLIMB NCT02614794 · Seagen Inc. DeepView → | HER2-positive unresectable locally advanced or metastatic breast cancer | Phase 2 | Deep | View | |||
| TAPUR NCT02693535 · American Society of Clinical Oncology DeepView → | advanced solid tumors, non-Hodgkin lymphoma or multiple myeloma | Phase 2 | Deep | View | |||
| MOUNTAINEER NCT03043313 · Seagen Inc. DeepView → | chemotherapy-refractory HER2-positive RAS wild-type metastatic colorectal cancer | Phase 2 | Deep | View | |||
| HER2CLIMB-02 NCT03975647 · Seagen, a wholly owned subsidiary of Pfizer DeepView → | previously treated HER2-positive locally advanced/metastatic breast cancer | Phase 3 | Deep | View | |||
| DESTINY-Breast07 NCT04538742 · AstraZeneca DeepView → | HER2-positive metastatic breast cancer | Phase 1/Phase 2 | Deep | View | |||
| HER2CLIMB-04 NCT04539938 · Seagen, a wholly owned subsidiary of Pfizer DeepView → | previously treated HER2+ locally-advanced or metastatic breast cancer | Phase 2 | Deep | View | |||
| MOUNTAINEER-03 NCT05253651 · Seagen, a wholly owned subsidiary of Pfizer DeepView → | first-line HER2+ metastatic colorectal cancer | Phase 3 | Deep | View | |||
| SGNTUC-019 NCT04579380 · Seagen, a wholly owned subsidiary of Pfizer DeepView → | previously treated advanced solid tumors with HER2 alterations | Phase 2 | Deep | View | |||
| compassHER2 RD NCT04457596 · Alliance for Clinical Trials in Oncology StandardView → | residual HER2-positive invasive breast cancer | Phase 3 | Standard | View | |||
| SAPPHO NCT06439693 · Dana-Farber Cancer Institute StandardView → | de novo HER2+ metastatic breast cancer | Phase 2 | Standard | View | |||